[go: up one dir, main page]

DE69835288D1 - Kombinationstherapie zur modulation der humanen sexualreaktion - Google Patents

Kombinationstherapie zur modulation der humanen sexualreaktion

Info

Publication number
DE69835288D1
DE69835288D1 DE69835288T DE69835288T DE69835288D1 DE 69835288 D1 DE69835288 D1 DE 69835288D1 DE 69835288 T DE69835288 T DE 69835288T DE 69835288 T DE69835288 T DE 69835288T DE 69835288 D1 DE69835288 D1 DE 69835288D1
Authority
DE
Germany
Prior art keywords
modulating
combination therapy
human sexual
sexual reaction
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835288T
Other languages
English (en)
Other versions
DE69835288T2 (de
Inventor
S Podolski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Publication of DE69835288D1 publication Critical patent/DE69835288D1/de
Application granted granted Critical
Publication of DE69835288T2 publication Critical patent/DE69835288T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69835288T 1997-05-19 1998-05-19 Kombinationstherapie zur modulation der humanen sexualreaktion Expired - Lifetime DE69835288T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4994797P 1997-05-19 1997-05-19
US49947P 1997-05-19
PCT/US1998/010230 WO1998052569A1 (en) 1997-05-19 1998-05-19 Combination therapy for modulating the human sexual response

Publications (2)

Publication Number Publication Date
DE69835288D1 true DE69835288D1 (de) 2006-08-31
DE69835288T2 DE69835288T2 (de) 2007-07-19

Family

ID=21962609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835288T Expired - Lifetime DE69835288T2 (de) 1997-05-19 1998-05-19 Kombinationstherapie zur modulation der humanen sexualreaktion

Country Status (17)

Country Link
EP (1) EP0996447B1 (de)
JP (2) JP4588809B2 (de)
KR (1) KR20010012721A (de)
CN (1) CN1262622A (de)
AT (1) ATE333279T1 (de)
AU (1) AU749703B2 (de)
BR (1) BR9809848A (de)
CA (1) CA2291160C (de)
DE (1) DE69835288T2 (de)
DK (1) DK0996447T3 (de)
ES (1) ES2270517T3 (de)
HK (1) HK1028197A1 (de)
IL (2) IL132853A0 (de)
NO (1) NO322079B1 (de)
NZ (1) NZ500921A (de)
PT (1) PT996447E (de)
WO (1) WO1998052569A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
CA2251255A1 (en) * 1998-10-20 2000-04-20 Mcgill University The use of dopaminergic agents in the management of sexual dysfunction
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
CA2366903A1 (en) * 1999-04-06 2000-10-12 Zonagen, Inc. Methods for modulating the human sexual response
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
US7678078B1 (en) 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
FR2680106B1 (fr) * 1991-08-09 1994-03-11 Corbiere Gerome Procede de realisation de formes pharmaceutiques stables d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues.
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
CN1113757A (zh) * 1994-06-24 1995-12-27 王儒新 一种性功能促进剂及其制备方法
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
JPH09110674A (ja) * 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物

Also Published As

Publication number Publication date
KR20010012721A (ko) 2001-02-26
EP0996447A1 (de) 2000-05-03
PT996447E (pt) 2006-12-29
JP2009280621A (ja) 2009-12-03
NZ500921A (en) 2002-11-26
EP0996447B1 (de) 2006-07-19
HK1028197A1 (en) 2001-02-09
AU7498098A (en) 1998-12-11
WO1998052569A1 (en) 1998-11-26
AU749703B2 (en) 2002-07-04
JP2001526686A (ja) 2001-12-18
ATE333279T1 (de) 2006-08-15
CN1262622A (zh) 2000-08-09
DK0996447T3 (da) 2006-11-13
NO995657L (no) 2000-01-18
CA2291160C (en) 2008-10-28
ES2270517T3 (es) 2007-04-01
IL132853A0 (en) 2001-03-19
NO322079B1 (no) 2006-08-14
JP4588809B2 (ja) 2010-12-01
BR9809848A (pt) 2000-06-27
IL132853A (en) 2010-04-15
DE69835288T2 (de) 2007-07-19
CA2291160A1 (en) 1998-11-26
NO995657D0 (no) 1999-11-18

Similar Documents

Publication Publication Date Title
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
EA200200208A1 (ru) Синергитическая композиция
BR9805544C1 (pt) Uso de um composto.
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0214407A (pt) Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
ID21698A (id) Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
ATE332903T1 (de) Kondensierte pyridoindolderivate
ES2157992T3 (es) Alcoxi-alquil-carbamatos de imidazo(1,2-a)piridinas.
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
ATE322898T1 (de) Inhibitoren von mycobakterien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition